CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
332.46MGBP453.07M · vs all stocks (USD)
Revenue (TTM)
57.29MGBP78.08M · vs all stocks (USD)
Profit Margin
-84.08%Beta
0.8350xvs all stocks
52-Week Change
-39.37%vs all stocks
Market Capitalization
332.46MGBP453.07M · vs all stocks (USD)
Enterprise Value
339.09MGBP462.11M · vs all stocks (USD)
Forward P/E
-7.29xPrice to Sales (TTM)
5.80xPrice to Book (MRQ)
52.50xEnterprise to Revenue
5.92xEnterprise to EBITDA
-10.73xProfit Margin
-84.08%Operating Margin
-31.35%Return on Assets (TTM)
-29.64%Return on Equity (TTM)
142.35%Revenue (TTM)
57.29MGBP78.08M · vs all stocks (USD)
Revenue per Share (TTM)
0.0110GBPUpdated Aug 21, 2026Quarterly Revenue Growth
6.60%Gross Profit (TTM)
29.92MGBP40.77M · vs all stocks (USD)
EBITDA (TTM)
-31.61MGBP-43.07M · vs all stocks (USD)
Net Income (TTM)
-48.17MGBP-65.65M · vs all stocks (USD)
Operating Cash Flow (TTM)
-32.52MGBP-44.32M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-24.17MGBP-32.94M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
55.04MGBPFY2025 · Jun 30, 2025Cost of Goods Sold
25.74MGBPFY2025 · Jun 30, 2025Gross Profit
29.30MGBPFY2025 · Jun 30, 2025Operating Income
-28.16MGBP-38.38M · vs all stocks (USD)
Pre-tax Income
-39.20MGBPFY2025 · Jun 30, 2025Income Tax Expense
932.00KGBPFY2025 · Jun 30, 2025Net Income
-40.13MGBPFY2025 · Jun 30, 2025EBIT
-32.51MGBPFY2025 · Jun 30, 2025EBITDA (Income Statement)
-24.08MGBPFY2025 · Jun 30, 2025Research & Development
15.38MGBPFY2025 · Jun 30, 2025Selling, General & Administrative
38.29MGBPFY2025 · Jun 30, 2025Non-operating Interest Income
382.00KGBPFY2025 · Jun 30, 2025Non-operating Interest Expense
6.69MGBPFY2025 · Jun 30, 2025EPS (Basic)
-0.0084GBPFY2025 · Jun 30, 2025EPS (Diluted)
-0.0084GBPFY2025 · Jun 30, 2025Basic Shares Outstanding
4.77BSharesFY2025 · Jun 30, 2025Diluted Shares Outstanding
4.77BSharesFY2025 · Jun 30, 2025Preferred Stock Dividends
0.00GBPFY2025 · Jun 30, 2025Operating Cash Flow
-32.73MGBPFY2025 · Jun 30, 2025Free Cash Flow
-35.99MGBPFY2025 · Jun 30, 2025Cash & Cash Equivalents (End of Period)
12.79MGBPFY2025 · Jun 30, 2025Starting Profit (CF Statement)
-39.20MGBPFY2025 · Jun 30, 2025Stock-based Compensation
871.00KGBPFY2025 · Jun 30, 2025Other Non-cash Items
6.35MGBPFY2025 · Jun 30, 2025Change in Accounts Receivable (CF)
266.00KGBPFY2025 · Jun 30, 2025Change in Other Assets/Liabilities
-1.02MGBPFY2025 · Jun 30, 2025Capital Expenditures
-3.26MGBPFY2025 · Jun 30, 2025Net Intangibles (CF)
-158.00KGBPFY2025 · Jun 30, 2025Sale of Investments
267.00KGBPFY2025 · Jun 30, 2025Net Investing Cash Flow
-3.00MGBPFY2025 · Jun 30, 2025Long-term Debt Issuance
40.31MGBPFY2025 · Jun 30, 2025Long-term Debt Payments
-5.64MGBPFY2025 · Jun 30, 2025Net Financing Cash Flow
34.68MGBPFY2025 · Jun 30, 2025Shares Outstanding
6.14BSharesUpdated Aug 21, 2026Float Shares
701.66MSharesUpdated Aug 21, 2026% Held by Insiders
88.78%vs all stocks
% Held by Institutions
0.01%vs all stocks
Total Cash (MRQ)
10.08MGBP13.74M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0020GBPUpdated Aug 21, 2026Total Debt (MRQ)
26.75MGBP36.46M · vs all stocks (USD)
Total Debt to Equity (MRQ)
6.30xCurrent Ratio (MRQ)
1.13xBook Value per Share (MRQ)
0.0010GBPUpdated Aug 21, 2026Total Assets
67.54MGBP92.05M · vs all stocks (USD)
Total Current Assets
34.68MGBPFY2025 · Jun 30, 2025Total Liabilities
95.74MGBPFY2025 · Jun 30, 2025Total Non-current Assets
32.87MGBPFY2025 · Jun 30, 2025Total Non-current Liabilities
68.54MGBPFY2025 · Jun 30, 2025Total Current Liabilities
27.19MGBPFY2025 · Jun 30, 2025Cash
12.59MGBPFY2025 · Jun 30, 2025Cash & Cash Equivalents
12.59MGBPFY2025 · Jun 30, 2025Accounts Receivable
2.85MGBPFY2025 · Jun 30, 2025Inventory
13.91MGBPFY2025 · Jun 30, 2025Accounts Payable
4.49MGBPFY2025 · Jun 30, 2025Short-term Debt
1.88MGBPFY2025 · Jun 30, 2025Long-term Debt
58.21MGBPFY2025 · Jun 30, 2025Common Stock (Book)
4.77MGBPFY2025 · Jun 30, 2025Retained Earnings
-235.23MGBPFY2025 · Jun 30, 2025Total Shareholders' Equity
-28.19MGBP-38.42M · vs all stocks (USD)
52-Week High
12.10GBXUpdated Aug 21, 202652-Week Change
-39.37%vs all stocks
Beta
0.8350xvs all stocks
50-Day MA
6.35GBXUpdated Aug 21, 2026200-Day MA
9.52GBXUpdated Aug 21, 2026Avg 10-Day Volume
1.10MSharesUpdated Aug 21, 2026Avg 30-Day Volume
550.90KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.0100GBPUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Kyverna Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ever Supreme Bio Technology Co., Ltd
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ClearPoint Neuro Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Nanjing Medlander Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cybin Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Guizhou Yibai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Editas Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Honz Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow